Anna Forsby

Dr. Anna Forsby

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2017 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
MLMarcel Leist
Marcel Leist
AGAhmed Ghallab
Ahmed Ghallab
RGRabea Graepel
Rabea Graepel
RMRosemarie Marchan
Rosemarie Marchan
RHReham Hassan
Reham Hassan
Jan G HengstlerJan G Hengstler
Jan G Hengstler

4 August 2016 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
BSBéla Z. Schmidt
Béla Z. Schmidt
MLMartin Lehmann
Martin Lehmann
SGSimon Gutbier
Simon Gutbier
ENErastus Nembo
Erastus Nembo
SNSabrina Noel
Sabrina Noel
ADAndrás Dinnyés
András Dinnyés

2 January 2015 in Critical Reviews in Toxicology
Verified
Journal Article
Closed access
PDF file
ABAnna Bal-Price
Anna Bal-Price
KCKevin M. Crofton
Kevin M. Crofton
MSMagdalini Sachana
Magdalini Sachana
TSTimothy J. Shafer
Timothy J. Shafer
MBMamta Behl
Mamta Behl
EFEllen Fritsche
Ellen Fritsche
The Adverse Outcome Pathway (AOP) framework provides a template that facilitates understanding of complex biological systems and the pathways of toxicity that result in adverse outcomes (AOs). The AOP starts with an molecular initiating event (MIE) in which a chemical interacts with a biological target(s), followed by a sequential series of KEs, which are cellular, anatomical, and/or functional changes in biological processes, that ultimately result in an AO manifest in individual organisms and populations. It has been developed as a tool for a knowledge-based safety assessment that relies on understanding mechanisms of toxicity, rather than simply observing its adverse outcome. A large number of cellular and molecular processes are known to be crucial to proper development and function of the central (CNS) and peripheral nervous systems (PNS). However, there are relatively few examples of well-documented pathways that include causally linked MIEs and KEs that result in adverse outcomes in the CNS or PNS. As a first step in applying the AOP framework to adverse health outcomes associated with exposure to exogenous neurotoxic substances, the EU Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) organized a workshop (March 2013, Ispra, Italy) to identify potential AOPs relevant to neurotoxic and developmental neurotoxic outcomes. Although the AOPs outlined during the workshop are not fully described, they could serve as a basis for further, more detailed AOP development and evaluation that could be useful to support human health risk assessment in a variety of ways.

1 June 2017 in Toxicology in Vitro
Verified
Journal Article
Closed access
JHJon Hamm
Jon Hamm
KSKristie Sullivan
Kristie Sullivan
ACAmy J. Clippinger
Amy J. Clippinger
JSJudy Strickland
Judy Strickland
SBShannon Bell
Shannon Bell
DADavid Allen
David Allen

1 April 2007 in Human & Experimental Toxicology
Verified
Journal Article
Closed access
AFAnna Forsby
Anna Forsby
BBBas Blaauboer
Bas Blaauboer
Risk assessment of neurotoxicity is mainly based on in vivo exposure, followed by tests on behaviour, physiology and pathology. In this study, an attempt to estimate lowest observed neurotoxic doses after single or repeated dose exposure was performed. Differentiated human neuroblastoma SH-SY5Y cells were exposed to acrylamide, lindane, parathion, paraoxon, phenytoin, diazepam or caffeine for 72 hours. The effects on protein synthesis and intracellular free Ca2+concentration were studied as physiological endpoints. Voltage operated Ca2 +channel function, acetylcholine receptor function and neurite degenerative effects were investigated as neurospecific endpoints for excitability, cholinergic signal transduction and axonopathy, respectively. The general cytotoxicity, determined as the total cellular protein levels after the 72 hours exposure period, was used for comparison to the specific endpoints and for estimation of acute lethality. The lowest concentration that induced 20% effect (EC 20) obtained for each compound, was used as a surrogate for the lowest neurotoxic level (LOEL) at the target site in vivo. The LOELs were integrated with data on adsorption, distribution, metabolism and excretion of the compounds in physiologically-based biokinetic (PBBK) models of the rat and the lowest observed effective doses (LOEDs) were estimated for the test compounds. A good correlation was observed between the estimated LOEDs and experimental LOEDs found in literature for rat for all test compounds, except for diazepam. However, when using in vitro data from the literature on diazepam's effect on gamma-amino butyric acid (GABA)A receptor function for the estimation of LOED, the correlation between the estimated and experimental LOEDs was improved from a 10 000-fold to a 10-fold difference. Our results indicate that it is possible to estimate LOEDs by integrating in vitro toxicity data as surrogates for lowest observed target tissue levels with PBBK models, provided that some knowledge about toxic mechanisms is known. Human & Experimental Toxicology (2007) 26, 333—338

1 August 1999 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
JDJ. DeJongh
J. DeJongh
MNM. Nordin-Andersson
M. Nordin-Andersson
BPB.A. Ploeger
B.A. Ploeger
AFAnna Forsby
Anna Forsby